333. Ray Chaudhuri K, Martinez-Martin P, Rolfe K.A, Cooper J, Rockett CB, Giorgi L, Ondo WG. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):105-13.
334. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90-9. doi: 10.1002/mds.23441. Epub 2010 Nov 18. PMID: 21322021; PMCID: PMC3072524.
335. Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014;37:116-122.
336. Яхно Н.Н., Нодель М.Р., Федорова Н.В., Левин О.С., Артемьев Д.В., Смоленцева И.Г., Кулуа Т.К. Эффективность и переносимость препарата Сталево при болезни Паркинсона. Неврологический журнал. 2007. N 6. С. 48-52.
337. Кулуа Т.К., Федорова Н.В., Поповкина O.A. Ночные моторные симптомы болезни Паркинсона и их коррекция трехкомпонентным препаратом леводопа/карбидопа/энтакапон. Журн. неврологии и психиатрии им. С.С.Корсакова. - 2011, № 9(2). С. 45-50.
338. Park KW, Jo S, Lee SH, Hwang YS, Lee D, Ryu HS, Chung SJ. Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson's Disease. J Mov Disord. 2020 Sep;13(3):205-212.
339. Videnovic A. Management of Sleep Disorders in Parkinsons Disease and multiple system atrophy. Movement Disorders 2017; 32(5):659-668.
340. Dowling G., Mastick J., Colling E, et.al. Melatonin for sleep disturbances in in PD. Sleep Med. 2005;6:459-466. Medeiros CA. Carvalhedo de Bruin PF, Lopes LA,Magalhaes MC, de Lourdes Seabra M, Sales de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254:459–464.
341. Matthew Menza , Roseanne DeFronzo Dobkin, Humberto Marin, Michael Gara, Karina Bienfait, Allison Dicke, Cynthia L Comella, Charles Cantor, Lee Hyer. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Randomized Controlled Trial. Mov Disord. 2010 Aug 15;25(11):1708-14.
342. Riemann D. et al. European guideline for the diagnosis and treatment of insomnia J Sleep Res. 2017 Dec;26(6):675-700
343. Loddo G. et al. The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice //Frontiers in neurology. – 2017. – Т. 8. C. 42.
344. Yang H, Petrini M.Effect of cognitive behavior therapy on sleep disorder in Parkinson's disease in China: a pilot study.Nurs Health Sci. 2012 Dec;14(4):458-63.
345. Nascimento CM, Ayan C, Cancela JM, Gobbi LT, Gobbi S, Stella F. Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson's and Alzheimer's disease patients.Geriatr Gerontol Int. 2014 Apr;14(2):259-664.
346. Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017 Apr 1;74(4):411-418].
347. Carlos Mauricio Oliveira de Almeida , Daniela Vianna Pachito, Manoel Alves Sobreira-Neto, Vitor Tumas, Alan Luiz Eckeli. Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. J Neurol Sci. 2018 Oct 15;393:63-68.
348. Moran Gilat, Alessandra Coeytaux Jackson, Nathaniel S Marshall, Deborah Hammond, Anna E Mullins, Julie M Hall, Bernard A M Fang, Brendon J Yee, Keith K H Wong , Ron R Grunstein, Simon J G Lewis. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. Mov Disord. 2020 Feb;35(2):344-349].
349. Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F,Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord 2012;27:559-561.
350. Paus S., Brecht H.M., Köster J. Sleep attacks, daytime sleepiness, and dopamine agonists in parkinson’s disease. Mov. Disord. 2003; 18 (6): 659–67.
351. Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L,Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep 2014;37:177-85.
352. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol. 2005 Jul;252(7):753-64. doi: 10.1007/s00415-005-0918-5. PMID: 15999234.
353. Zahodne L. B., Fernandez H. H. Pathophysiology and treatment of psychosis in Parkinson’s disease //Drugs & aging. – 2008. – Т. 25. – №. 8. C. 665-682
354. Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012;35:61-66.
355. Sarah Horn , Hayley Richardson , Sharon X Xie , Daniel Weintraub , Nabila Dahodwala. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2019 Dec;69:119-124.
356. David Burn , Murat Emre, Ian McKeith, Peter Paul De Deyn, Dag Aarsland, Chuanchieh Hsu, Roger Lane. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006 Nov;21(11):1899-907
357. Yoon-Sang Oh , Joong-Seok Kim, Phil Hyu Lee.. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia J Mov Disord 2015 May;8(2):98-102.